Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Bao
Bao Chun Lu, Beijing CN
| Patent application number | Description | Published |
|---|---|---|
| 20110267811 | SHADING PANEL FOR DISPLAY SYSTEM - A shading panel is described for shading light emitting elements of a light emitting diode display system. The shading panel defines a substantially plane panel surface having an upper border and a lower border, the shading panel comprising at least one column of at least two openings aligned according to a column direction, each opening being suitable to receive at least one light emitting element. For each pair of adjacent openings of the at least one column of openings, the shading panel comprises a first shading louver and a second shading louver, the first shading louver being positioned closer to the opening of the pair of openings closest to the upper border, the second shading louver being positioned closer to the opening of the pair of openings closest to the lower border. The height of the first shading louver is smaller than the height of the second shading louver. | 11-03-2011 |
Bao Dequan, Shenzhen CN
| Patent application number | Description | Published |
|---|---|---|
| 20100143955 | REAGENT FOR BLOOD ANALYSIS AND METHOD OF USING THE SAME - A reagent for blood analysis includes: (1) a compound having the general formula I; and (2) at least one surfactant selected from cationic surfactants and nonionic surfactants. In another aspect a method for differentiating and counting blood cells is provided, the method includes the following steps: (a) mixing a blood sample with the reagent for blood analysis according to the present disclosure to form a cell suspension; (b) detecting scattered light signals and fluorescence signals of cells in the blood sample; and (c) differentiating and counting the cells in the blood sample based upon the scattered light signals and fluorescence signals. The reagent for blood analysis may be effective for identifying and counting erythroblasts and/or basophils in a blood sample to be detected, and meanwhile counting leukocytes therein. | 06-10-2010 |
Bao He, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20100261787 | PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION - The invention relates to application of 4,4′-diphenylmethane-bis(methyl)carbamates (DPMC) extracted and isolated from Cortex Mori and preparation of medicine for diabetic nephropathy. The pharmaceutical composition is made up of DPMC as active ingredient and the normal drug carriers, and the weight percentage of active ingredient is 0.1-99.5%. For the remarkable effect of prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients. | 10-14-2010 |
| 20100267819 | PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION - The invention relates to a pharmaceutical composition for diabetic nephropathy and its preparation, and the application in preparing of medicine for diabetic nephropathy. The pharmaceutical composition is made up of at least one of 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin as active ingredient, and the weight percentage of active ingredient is 0.1-99.5%. Moreover, the pharmaceutical composition is mainly used for the prevention and cure of diabetic nephropathy. For the abundant material, remarkable effect on prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients. | 10-21-2010 |
| 20110053872 | Pharmaceutical Composition For Preventing And Treating Diabetic Nephropathy And The Preparation Method Thereof - The present invention relates to a pharmaceutical composition for preventing and treating diabetic complications, mainly referring to diabetic nephropathy, and the pharmaceutical composition comprises one or both of calycosin and calycosin-7-O-β-D-glucoside as 0.1˜99.5% by weight based on the total weight of the composition, and the conventional drug carrier. The pharmaceutical composition could significantly prevent and treat diabetic nephropathy, with the convenience of quality control and administration, which provides a new drug candidate for patients with diabetic nephropathy. | 03-03-2011 |
Bao Tran, Santa Clara, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100099617 | Secreted proteins - The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP. | 04-22-2010 |
Bao Xiangfei, Shanghai CN
| Patent application number | Description | Published |
|---|---|---|
| 20090286960 | Method of purifying apolipoprotein A-1 - A first method of purifying apolipoprotein A-1 includes mixing plasma fraction IV with a 1-8 M urea solution to form a pretreatment solution; loading the pretreatment solution to a first anion chromatography column, and then eluting to obtain an apoA-1 protein solution; and loading the apoA-1 protein solution to a second anion chromatography column, and eluting to obtain pure apoA-1 protein. A second method includes dissolving plasma fraction IV in a buffer to produce a pretreatment solution; adding NaCl to the pretreatment solution and cooling it to form apoA-1 precipitate; collecting and reconstituting the apoA-1 precipitate; loading the reconstituted apoA-1 to an anion exchange column; and eluting apoA-1 from the column. | 11-19-2009 |